DDInter666 DDInter1376
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Eribulin {u} (Compound) treats {v} (Disease) breast cancer
Eribulin {u} (Compound) binds {v} (Gene) TUBB
Eribulin {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Eribulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Verapamil
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paliperidone
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Eribulin (Compound) treats breast cancer (Disease)
Eribulin (Compound) binds TUBB (Gene)
Eribulin (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Eribulin may cause a minor interaction that can limit clinical effects when taken with Verapamil
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Eribulin may lead to a major life threatening interaction when taken with Escitalopram